

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number  
**WO 2004/041231 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 7/42, 35/78**
- (21) International Application Number:  
PCT/EP2003/011847
- (22) International Filing Date: 24 October 2003 (24.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/424,712 8 November 2002 (08.11.2002) US
- (71) Applicants (*for all designated States except US*):  
**MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse  
200, 64293 Darmstadt (DE). **NATREON INC.** [US/US];  
14A Jules Lane, New Brunswick, NJ 08901 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **CHAUDHURI, Ratan**  
[US/US]; 15 Sherbrooke Drive, Lincoln Park, NJ 07035  
(US).
- (74) Common Representative: **MERCK PATENT GMBH**,  
Frankfurter Strasse 200, 64293 Darmstadt (DE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 2004/041231 A1**

(54) Title: METHOD FOR PROTECTION OF SKIN AGAINST SUN-INDUCED DAMAGE BY ORAL ADMINISTRATION OF AN EXTRACT OF EMBLICA OFFICINALIS (syn. PHYLLANTHUS EMBLICA)

(57) Abstract: This invention relates to sun protection, and, more particularly, to a method for sun protection of skin by oral administration of an extract of the *Embllica officinalis* (syn. *Phyllanthus emblica*) plant. And to dosage forms suitable for this purpose.

**METHOD FOR PROTECTION OF SKIN AGAINST SUN-INDUCED  
DAMAGE BY ORAL ADMINISTRATION OF AN EXTRACT OF EMBLICA  
OFFICINALIS (syn. PHYLLANTHUS EMBLICA)**

5

Field of the Invention

This invention relates to sun protection, and, more particularly, to a method for sun protection of skin by oral administration of an extract of the *Embl*

10

*officinalis* (syn. *Phyllanthus emblica*) plant.

Description of the Prior Art

The predominant extracellular matrix component of the dermis and a variety of other human tissues is collagen, a super family of closely related, yet genetically distinct proteins. Each of the genetically distinct collagen

15

types has an important functional role within its compartmentalized distribution in the skin.

Extrinsic aging of the skin comprises changes that represent the accumulation of the many environmental insults to the skin. The most important of these insults is obviously long-term sun exposure. The changes in collagen quantity and its structure, skin elasticity and extensibility are exaggerated in photo damaged skin. A recent study suggests that the decline in dermal collagen is greater in extrinsically photo damaged skin than in intrinsically aged skin.

20

In actinically damaged skin (skin damaged by the chemical action of the sun's rays), the significantly increased iron content drives the production of highly reactive oxygen species (ROS) with subsequent tissue damage and long-term consequences like cancer or premature aging of the skin. UV-inducible genes involved in this pathological degradation comprise several proteases, among them matrix-degrading metalloprotease (MMPs), which contribute to degradation of connective tissue compounds such as collagen and thus cause wrinkle formation, loss of elasticity and promote

25

30

invasion and metastasis of skin cancer. The release of iron from iron-storage proteins at the cellular level due to U.V. exposure has been identified as the main source of oxidative stress.

5 Exposure to the sun causes premature aging of the skin. Premature aging shows up on the skin as lines, wrinkles, age spots, freckles, dryness and uneven skin tone. Photo-aging also causes collagen to break down which reduces the skin's elasticity and firmness. While these signs show that skin has been damaged, and that is a concern, it also reduces the appearance of the individual and makes them appear, in many cases, 10 much older than they really are. This in and of itself can be very distressing, especially to women as the majority of photo-aging occurs on skin that is exposed everyday, such as the skin on the face, neck, chest, hands and arms and is therefore seen. Creams, lotions and makeup can attempt to mask the problem but cannot reverse damage caused by photo-aging. 15 What is really needed is a product which can help protect and reverse the skin-damaging effects of the sun by nourishing and replenishing the skin from within. Until now, no such product existed, that is until the invention of this application.

20 Ultraviolet radiation (UVR)-induced inflammatory response is one of the prevailing mechanisms proposed to account for the majority of the UVR-dependent increases in ROS as well as UVR-dependent oxidative damage to the skin. In addition, the proinflammatory and redox-regulated transcription factor NF- $\kappa$ B has been identified as among the primary molecules targeted during the signal transduction initiated by UVR in 25 human skin. As a result, UVR stimulates the expression of a wide variety of proinflammatory genes such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin-1 $\alpha$  (IL-1 $\alpha$ ), interleukin-6 (IL-6), and interleukin-8 (IL-8), which contain nuclear factor- $\kappa$ B (NF- $\kappa$ B)-binding sites in their 5' flanking region.

30 Because the inflammatory response plays a substantial role in UVR-induced oxidative stress and damage in the skin through the elevation of

ROS levels, antioxidants with anti-inflammatory properties are considered to counteract the damaging effects of UVR.

For example, Ghosal, S., in U.S. Pat. 6,124,268, described a natural antioxidant blend obtained by extraction from the *Emblica officinalis* plant, which could be used as a sunscreen when applied as a spray lotion, aqueous gel, or cream, to the skin of the user. This patent also describes orally administrable compositions, for example with vitamins to take advantage of the antioxidant property of the extract described therein, but with no suggestion that such composition can protect skin from sun-induced damage. Conversely, Lorenz, R., in U.S. Pat. 6,433,025 disclosed a method of retarding or preventing sunburns by oral administration of astaxanthin.

Accordingly, it is an object of this invention to provide a method of sun protection of skin against UVR-induced erythema by oral administration of an extract composition of the *Emblica officinalis*.

#### SUMMARY OF THE INVENTION

What has been discovered herein is that an antioxidant composition based on an extract of the *Emblica officinalis* plant can provide effective sun protection of skin when taken orally by the user.

#### DETAILED DESCRIPTION OF THE INVENTION

The antioxidant composition in the present invention comprises an extract of *Emblica officinalis*, e.g. that of U.S. 6,124,218 and preferably a standardized extract of low molecular weight (<1000) hydrolysable tannins, suitably over 40%, preferably 50-80%, w/w, of Emblicanin A, Emblicanin B, Pedunculagin and Punigluconin, with low levels, <1%, w/w, preferably <0.6%, of total flavonoids, which standardized extract differs from the extract described by Ghosal. The total flavonoids levels in the standardized extract does not impair the desired elegant off white-to-yellow color of the composition. In comparison, commercial competitive products,

which have significantly higher contents of total flavonoids, exhibit a significantly darker color. Also, the desired concentrations of the rutin species of flavonoids (3',4',5',7-tetrahydroxy-flavone-3-O-rhamnoglucoside) in the standardized extract of the invention are less than 1.0%, preferably less than 0.01%, with a value of 0.001 to 0.01% being particularly preferred. The most preferred concentrations of the components are on a percent by weight basis of the total dried extract:

TABLE 1

Standardized Extract Composition

Component	Most Preferred Concentrations (% by Weight)
Emblicanin A	20-35
Emblicanin B	10-20
Pedunculagin	15-30
Punigluconin	3-12
Total Flavonoids	<1

The standardized composition may exhibit average percentage deviations from these preferred values of:

TABLE 2

Component	Preferred Deviation	Most Preferred Deviation
Emblicanin A	± 10%	± 5%
Emblicanin B	± 10%	± 5%
Pedunculagin	± 10%	± 5%
Punigluconin	± 10%	± 5%
Total Flavonoids	± 10%	± 5%

The preferred antioxidant compositions of the invention can be obtained by removal of the total flavonoids by reverse-phase column chromatography, or HPLC, using a solvent system of acetonitrile, water/phosphoric acid (20/80/1), or other solvent combinations, as they elute faster than the low molecular-weight tannins. Also, by selection of geographical location, the *Phyllanthus emblica* fruit extract can provide a substantially lower level of the total flavonoids (< 1.0%). More particularly, it has been observed that medium-sized fruits collected from some parts of eastern India, during November-February, after water extraction and drying, yield the preferred antioxidant composition as a powder with the desired low content of total flavonoids. Accordingly, by analyzing the total flavonoids content of extracts and selecting extracts that contain the desired low content of total flavonoids, it is possible to prepare the desired standardized extract in a reproducible manner.

In the context of the present invention the term "flavonoids" include a family of compounds, which exhibit a peak at 350 nm when analyzed by UV spectral data. Examples of flavonoids include but are not limited to flavonols and flavones, a species thereof being rutin as discussed above.

In a preferred embodiment of this invention a substantially water-soluble (over 95% by weight) extract of *Phyllanthus Emblica* comprising less than 5% by weight of polymeric tannins, with substantially no black specks and at high levels, e.g. over 75% by weight of bio-active, low molecular-weight hydrolysable tannins having molecular weights below 1,000 is used. This extract can be obtained by a process which removes oligomeric and polymeric tannins. A suitable process comprises the following steps: 1) providing an extract of *Phyllanthus Emblica* either resulting from the original extract from the plant, or from a suspension of a powdered composition obtained after the extract is processed, e.g. after a drying step; 2) If necessary, physically separating the black specks and/or precursors thereof and/or polymeric tannins from the water-soluble components, for example by filtration with the use of a filter aid; 3) If

desired, concentrating the resultant aqueous solution of the enriched composition of *Emblica officinalis*, for example to a dry powder.

The antioxidant composition of present invention is truly innovative as it uniquely provides the four features of Dermal Defense

5

- No Pro-Oxidation Activity
- Inhibition of Collagenase & Stromelysin-1 Activity
- Iron and Copper Chelation Activity
- Cascading Effect

10

**No Pro-Oxidation Activity:** To control oxidative processes, i.e. to reduce, if not prevent their harmful effects to skin, diverse antioxidants can be used to protect skin from photo-damage. When a general use of antioxidants is advocated, it is often disregarded that these compounds not only function as antioxidants, but (intrinsically) have pro-oxidant action as well, especially in the presence of transition metals like iron and copper. Release of iron from the iron-storage protein ferritin under UV-light has been ascribed to be the main source of oxidative stress. The consequent release of potentially harmful free iron within the cells will clearly exacerbate the damaging effects of photoperoxidation and is likely to be of central importance to both reversible and degenerative damage to the skin after exposure to UV light. It has been shown that the iron content of the human epidermis is three-fold greater in sun-exposed areas than in non-exposed body sites. Iron exerts its toxicity through a series of reactions with reactive oxygen species called the Fenton reaction, generating the highly toxic hydroxyl radical with subsequent damage to biomolecules. The antioxidant of the present invention is completely free of pro-oxidation activity induced by transition metals whereas well-known antioxidants like Vitamin C, Vitamin E, proanthocyanidins (from pine and grape), Superoxide Dismutase and Glutathione do exhibit pro-oxidative activity.

25

30

**Inhibition of Collagenase Activity:** The antioxidant of the present invention is unique in that it inhibits collagenase activity (collagenase is one of the MMP's) which digests collagen and therefore degrades collagen. Exposure to UV tends to increase the expression of the collagenase enzyme which contributes to the visible signs of aging. The antioxidant of the present invention is able to block this enzyme activity and thereby reduces the destruction of collagen. Literature data shows that the protection of existing collagen is more important than stimulating collagen production (EF Bernstein and J Uitto, Clinics in Dermatology, 14, 143-151, 1996).

**Inhibition of Stromelysin-1 Activity:** Stromelysin-1 has a much broader substrate specificity than collagenase as it degrades various proteoglycan components of the extracellular matrix as well as fibronectin and laminin. Exposure to UV tends to increase the expression of the stromelysin-1 enzyme which contributes to the visible signs of aging. The antioxidant of the present invention is able to block this enzyme activity and thereby reduces the destruction of extracellular matrix proteins.

**Iron and Copper Chelation Activity:** Iron is the primary growth factor for all living cells. Most of the iron in the body resides in the blood stream. However, not all iron that enters the circulation can be carried by hemoglobin. If iron circulate through the blood stream unattached to a protein, what is called "free iron" they can wreak havoc, promoting oxidative stress. Iron-induced oxidation occurring within fatty tissues is called lipid peroxidation. For example, neurons (nerve cells) in the brain and nervous system are lined with fat called myelin and are very vulnerable to destruction by excessive levels of unbound iron.

The antioxidant of the present invention is a very efficient iron and copper chelator. Iron and copper are the principal players involved in the degradation of collagen and free radical damage which causes premature



aging and photodamage to the skin. Altering the reduction potential of iron to disfavor reaction with  $H_2O_2$  or blocking available sites on the iron to which  $H_2O_2$  might attach may provide a solution to stop transition metal-induced oxidation. These two principles are important in the design of  
5 chelators having antioxidant functionality for skin care use. The antioxidant of the present invention has all the attributes of an ideal antioxidant but no pro-oxidant activity induced by transition metals because of its excellent chelating property for  $Fe^{3+}$  and  $Cu^{2+}$  thereby eliminating the generation of the hydroxyl radical and its detrimental effects on skin, most significantly  
10 when skin is exposed to ultraviolet light.

**Cascading Effect:** The antioxidant of the present invention is one of a very small group of antioxidants providing a unique "cascading effect" which potentiates free radical scavenging activity by allowing the actives to  
15 continuously recycle to remain active for a longer period of time. While most antioxidants go from an active to an inactive role, the antioxidant of the present invention utilizes a multilevel cascade of antioxidant compounds resulting in a totally unique prolongation of its antioxidant capabilities.

20 A further embodiment of the current invention is a dosage form suitable for oral administration, characterized in that it comprises an extract of *Embllica officinalis*.

25 The dosage form preferably includes excipients suitable for such oral administration. The dosage form can be a tablet or a capsule or an elixir or suspension or a drink.

30 The dosage form may contain other ingredients capable of retarding, preventing and reversing the sign of skin photo-damage.

Nutritional supplements take many forms, varying in some instances with the intended application. They have been used in the form of liquids, pills or tablets and confectionery bars to supply diets with additional vitamins, minerals or other food groups. Protein supplements are available  
5 commercially in several forms, such as powders, tablets and self-supporting solid structures. The powders are typically sprinkled on or mixed with other foods and most typically mixed with a liquid such as water or milk. Flavoring agents and other additives are typically used to make the supplement more palatable and more easily dispersed in a liquid medium.  
10 The self-supporting solid structures are available commercially, typically as confectionery bars, e.g. "candy" bars. Like their powdered counterparts, they usually contain flavoring agents and other additives intended to provide better texture and palatability.

The type of physical activity required by many types of work and athletic  
15 pursuits place greater demands on the bodies of those people involved in such endeavors, requiring consumption of high levels of certain types of nutrients. Additionally, the presence of high levels of iron and copper in sweat cause much greater oxidative stress to skin and eventual photo-aging and wrinkle formation.

20 Therefore, in one preferred embodiment of the invention, the dosage form is a nutritional supplement, preferably in the form of liquids, powders, pills or tablets and confectionery bars, especially preferred a baked, edible, high protein product. One especially preferred dosage form comprises a) at  
25 least 0.1% *Emblica officinalis* extract, b) a mixture of high protein components, c) flour, d) leavening agent, e) sweetener, and f) water. Additionally the dosage form may comprise a flavor component for imparting a characteristic taste to said nutritional composition selected from the group consisting of water soluble natural or artificial extracts that include  
30 apple, banana, cherry, cinnamon, cranberry, grape, honeydew, honey, kiwi, lemon, lime, orange, peach, peppermint, pineapple, raspberry, tangerine, watermelon, wild cherry and equivalents thereof; being in the overall range

of 0.10% to 2.0% by weight of said dry composition and/or a colorant component for imparting a characteristic color to said nutritional composition selected from the group consisting of water soluble natural or artificial dyes of blue, green, orange, red, violet, and yellow; iron oxide dyes, ultramarine pigments of blue, pink, red, and violet; and equivalents thereof; being in the overall range of 0.10% to 2.0% by weight of said dry composition.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated.

#### EXAMPLE 1

Fresh *Emblica officinalis* fruit (5 kg) was finely pulped and mixed with water (2-liter), containing sodium chloride (1% w/w). The mixture was left standing at room temperature for about 12 hours. Then the mixture was stored in the cold (10°C.) for 3 days. Thereafter it was filtered through a thin cloth and the filtrate was spray-dried. The antioxidant fraction in the spray-dried blend was about 0.1 g/100 g of pulp as determined by high-pressure thin layer chromatography (HPTLC). Some free gallic acid (1.8 g/100 g of pulp), and monosaccharides and starches (glucose, rhamnose, galactose, etc.) (12 g/100 g of pulp) also was present in the blend.

The following examples have not, necessarily, been conducted, but are instead illustrative of the invention.

EXAMPLE 2  
EXTRACT TABLETS AND CAPSULES

5		Composition	Quantity per
	Ingredient	(w/w, in %)	tablet (mg)
	1. Extract of Invention (EX. 1)	60.0	250.0
	2. Avicel pH 101	20.0	84.0
	3. Starch 1500	17.5	75.5
10	4. Stearic acid, N.F. (powder)	2.0	8.5
	5. Cab-O-Sil	0.5	2.0

Note: Extract is granulated with starch paste to make it a free-flowing powder. Blend all the ingredients, except 4, for 25 min. in a blender.  
15 Screen in 4 and blend for an additional 5 min. Compress into tablets using 7/16-in standard concave tooling. Alternately, the blended material can be filled into appropriate capsules.

EXAMPLE 3  
EXTRACT TABLETS AND CAPSULES

20		Composition	Quantity per
	Ingredient	(w/w, in %)	tablet (mg)
	1. Extract of Invention (Ex. 1)	12.26	27.60
25	2. Sodium ascorbate, USP	36.26	81.60
	3. Avicel pH 101	17.12	38.50
	4. Sodium saccharin, (powder), N.F.	0.56	1.25
	5. DiPac	29.30	66.00
	6. Stearic acid, N.F.	2.50	5.60
30	7. Imitation orange flavor	1.0	2.25
	8. FD & C Yellow #6 dye	0.5	1.12
	9. Cab-O-Sil	0.5	1.12

---

Blend all the ingredients, except 6, for 20 min. in a blender. Screen in 6 and blend for an additional 5 min. Compress into tablets using 7/16-in standard concave tooling.

5

10

15

20

25

30

- 13 -

EXAMPLE 4EXTRACT SYRUP

5

Ingredient No.	Ingredient	Quantity per 100 mL
1	Extract of Invention	250 mg - 2 gm
2	Excipients	<u>q.s</u>

EXAMPLE 5

10

EXTRACT BEVERAGE

15

Ingredient No.	Ingredient	Quantity per 500 mL
1	Extract of Invention	10 mg -2 gm
2	Excipients: Carbonated Water, Food Starch-Modified, High Fructose Corn Syrup and/or Sucrose and/or Sugar, Sodium Benzoate, Caffeine, Glycerol Ester of Wood resin, Flavors, Colors	<u>q.s</u>

20

25

30

EXAMPLE 6  
EXTRACT CEREAL

5	Ingredient		Quantity per
	No.		
			1 Kg
	1	Extract of Invention	500 mg - 10 gm
10	2	Excipients: Whole Grain Oats, Oat Bran,	<u>q.s</u>
		Sugar, Modified Corn Starch, Brown	
		Sugar Syrup, Salt, Calcium Carbonate,	
		Trisodium Phosphate, Wheat Flour,	
15		Vitamin E (Mixed tocopherols), Zinc &	
		Iron (Mineral nutrients), Niacinamide (A B	
		Vitamins), Vitamin B6 (Pyridoxine Hcl),	
		Vitamin B2 (Riboflavin), Vitamin B1	
		(Thiamin Mononitrate), Vitamin A	
		(Palmitate), Vitamin A B (Folic acid),	
20		Vitamin B12, Vitamin D	
25			
30			

EXAMPLE 7EXTRACT NUTRITION BAR

5	<hr/>		
	Ingredient	Ingredient	Quantity per
	No.		50 g
	<hr/>		
	1	Extract of Invention	50 mg - 250 mg
10	2	Excipients: Mixed Fruit Juice	<u>q.s</u>
		Concentrates and Natural Grain Dextrins,	
		Brown Rice Syrup, Peanut Butter, Whey	
		Protein Concentrate, Peanut Flour,	
15		Agave Nectar, Honey, Rice Flour,	
		Calcium Caseinate, Natural Flavors, Salt,	
		Whey, Flax Seeds, Soy Protein Isolate,	
		Lecithin, Canola Oil, Vitamin E (Mixed	
		tocopherols).	

20

EXAMPLE 8METAL CHELATION ABILITY OF EXTRACT OF INVENTION

25 Iron-catalyzed formation of hydroxyl radical from superoxide anion radical and hydrogen peroxide requires the availability of at least one iron coordination site that is either empty or occupied by a readily dissociable ligand, such as water. This coordination with water may be completely displaced by stronger ligands like azide ( $N_3^-$ ) anion. This principle was

30 applied to determine if any coordination site is free in the  $Fe^{3+}$ -antioxidant complex by UV spectrophotometric method (E. Graf *et al.* "Iron-catalyzed hydroxyl radical formation, stringent requirement for free iron coordination



site" *J. Biol Chem.* 1984 259:3620-3624.; A. E. Martell *et al.*, in *Advances in Catalysis*, IX (A. Farakas, ed.), Academic Press, New York, NY, 319, 1957). Of all the  $\text{Fe}^{3+}$  chelates tested, only the Extract of Invention lack water in the coordination sphere (that is, the complex is fully and stably saturated and incapable of pro-oxidant activity *via* the formation of oxo-ferryl radical). All other antioxidants/chelators showed disparate coordination site(s) thereby allowing the formation of oxo-ferryl radical and manifesting a pro-oxidant effect, particularly at low concentrations. The Extract of Invention, being the most effective iron chelator, would prevent oxidative stress-induced damage caused by radicals and loose transition metal ions.

The results are recorded in Table 3 below:

TABLE 3

Ultraviolet Spectral Data of  $\text{Fe}^{3+}$ -Chelators\*

Chelator / Antioxidant	Absorption Maxima of Complex ( $\lambda_{\text{max}}$ in nm)	
	With $\text{Fe}^{3+}$	$\text{N}_3$ Induced Shift
EDTA	241, 283	241, 283, <u>410</u>
Extract of Invention	241, 294, 353, 377	241, 294, 353, 377 / No Shift
Pine Antioxidant	241, 294, 353, 384	241, 294, 353, <u>400</u> , <u>440</u>
Vitamin C	238, 262	241, 266, <u>295</u>
Grape Antioxidant	247, 295, 353, 396	247, 295, 353, <u>415</u> , <u>430</u>
Gree Tea	240, 272, 324, 390	240, <u>277</u> , 325, 390
Antioxidant		
Trolox C	240, 284	240, <u>273</u> , 284, <u>360</u>
Gallic Acid	247, 295, 337	247, 295, <u>353</u> , <u>412</u>

\* The peak positions are obtained from differential spectroscopic scans of

1.0 mM Fe<sup>3+</sup> and 5 mM chelator, 1M NaN<sub>3</sub>, 50 mM phosphate buffer, pH 7.4, vs. the same solution without sodium azide

5 TABLE 4

Ultraviolet Spectral Data of Cu<sup>2+</sup>-Chelators\*

	Chelator / Antioxidant	Absorption Maxima of Complex ( $\lambda_{\text{max}}$ in nm)	
		With Cu <sup>2+</sup>	N <sub>3</sub> Induced Shift
10	EDTA	240, 278	241, 279, <u>354</u>
	Extract of Invention	240, 272, 313	240, 272, 313 / No Shift
	Pine Antioxidant	239, 279, 302, 331	239, 280, 307, <u>430</u>
	Vitamin C	239, 263	239, 263, <u>284</u> , <u>364</u>
	Grape Antioxidant	240, 277, 328	240, 277, 328, <u>359</u>
15	Trolox C	241, 288	241, <u>261</u> , <u>352</u> , <u>440</u>
	Gallic Acid	240, 258, 321	240, 258, <u>331</u> , <u>463</u>

\*The peak positions are obtained from differential spectroscopic scans of  
 20 1.0 mM Cu<sup>2+</sup> and 5 mM chelator, 1M NaN<sub>3</sub>, 50 mM phosphate buffer, pH 7.4, vs the same solution without sodium azide.

EXAMPLE 9

25 CONTEMPLATED TEST PROTOCOL FOR EVALUATION AND  
COMPARISON OF THE EXTRACT COMPOSITION OF INVENTION TO  
ALTER UV-INDUCED ERYTHEMA BY ORAL ADMINISTRATION

Specifically, this extract food supplement, after oral administration for 8  
 30 weeks, in an amount of 1-500 mg/day should increase the UV radiation  
 necessary to produce a minimal erythematol dose (MED). Erythema would  
 then be evaluated by expert visual assessment. Minolta Chromameter

readings would be performed on baseline skin before and after 4 and 8 weeks of usage to evaluate for skin lightening potential of the extract food supplement.

5 1. INCLUSION CRITERIA

a. 36 healthy male and female subjects of skin types II-III (described below) would be selected for the study.

	<u>Skin Type</u>	<u>Sunburn and Tanning History</u>
10	I	Always burns easily; never tans (sensitive)
	II	Always burns easily; tans minimally (sensitive)
	III	Burns moderately; tans gradually (normal)
	IV	Burns minimally; always tans well (normal)
	V	Rarely burns; tans profusely (insensitive)
15	VI	Never burns; deeply pigmented (insensitive)

b. Ages 18-60 years old.

c. Absence of any visible skin disease which might be confused with a skin reaction from the test material.

20

2. EXCLUSION CRITERIA

a. Subjects with a history of abnormal response to sunlight or those taking medication, which might produce an abnormal response to sunlight, are excluded from the study.

25 b. Subjects exhibiting current sunburn, suntan, uneven skin tone or visible skin disease, which might interfere with evaluation of test results, are excluded from the study.

c. Pregnant or lactating females are excluded.

d. Subjects who regularly use UVA sunbeds.

30 e. Subjects with a history of lupus, erythematosus, or skin cancer.

f. Subjects who are taking any vitamin supplements within 2 weeks prior to the start of the study.

### 3. LIGHT SOURCE

A Xenon Arc Solar Simulator (150 w) would be used as the source of ultraviolet light irradiation (Solar Light Company, Philadelphia, PA). This instrument, described in detail in J. Invest. Dermatol. 53, 192 (1969), provides a spectral output in the ultraviolet range comparable to that of natural sunlight. WG-320 and UG-11 filters are used to provide a basic UV-A and UV-B wavelength spectrum, with wavelength ranges of 290-400 nm.

The lamp output would be measured with a UV intensity meter (Model PMA 2100 with a UVB detector, Solar Light Company, Philadelphia, PA) before and after the test period.

### 4. METHODOLOGY

The study would be performed by randomized, controlled trials with 36 volunteers randomly selected and divided into 2 groups consisting of 18 subjects each. 18 would be assigned to the orally administered group and 18 to the control group.

### 5. BASELINE

One-week prior to the start of the study, and again on the first day of the study, the subjects would arrive at the laboratory for determination of their MED values and the mean of these two values would be taken as the baseline MED value.

#### Minimal Erythematous Dose (MED)

The MED is defined as the time interval or dosage of UV light irradiation sufficient to produce a minimal, perceptible erythema on untreated skin. The MED of each subject would be determined by a progressive sequence of timed UV light exposures, each of which would be graduated incrementally by 25% over that of the previous exposure.

16 to 24 hours after irradiation, the sites would be evaluated for erythema according to the following scoring system:

- |   |     |                               |
|---|-----|-------------------------------|
|   | 0   | Negative, no visible reaction |
| 5 | 0.5 | Minimal erythema              |
|   | 1   | Defined erythema              |
|   | 2   | Moderate erythema             |
|   | 3   | Severe erythema               |

10        In addition to the visual assessments of the MED, readings of Baseline skin would be taken using the Minolta Chroma Meter. The L\*a\*b\* color notation system would be used to evaluate if there is a change in color over the duration of the study. Measurements would be made in triplicate and the average would be used as the data point.

15        Subjects in the treated groups would be instructed to administer orally 2 tablets of the extract composition of invention twice daily for 8 weeks. Subjects would be instructed to remain out of the sun and to keep a daily diary to document compliance.

20        Week 2

      The subjects would then return to the laboratory for determination of MED values. The subjects would be irradiated as described above adjacent to the Baseline MED. The MED would be evaluated 16 to 24 hours after irradiation using the scoring system listed above.

25

Week 4

      The subjects would then return to the laboratory for determination of MED values. The subjects would be irradiated as described above adjacent to the Baseline MED. Minolta Chroma Meter readings would be  
30        taken on Baseline skin as described above.

      The MED would be evaluated 16 to 24 hours after irradiation using the scoring system listed above.

Week 8

5 The subjects would return to the laboratory for determination of MED values. The subjects then would be irradiated as described above adjacent to the Baseline MED. Minolta Chroma Meter readings would be taken on Baseline skin as described above.

The MED would be evaluated 16 to 24 hours after irradiation using the scoring system listed above.

10 At the conclusion of the study, the pre- and post-study MED's as well as the Chroma Meter readings would be compared to determine if any significant changes are observed.

## EXAMPLE 10

15

CONTEMPLATED STROMELYSIN-1 AS A BIOMARKER FOR  
EVALUATION OF THE EXTRACT COMPOSITION OF INVENTION TO  
ALTER UV-INDUCED SKIN DAMAGE BY ORAL ADMINISTRATION

- 20 1. Level of Stromelysin-1 in serum of the human volunteers before and after sun exposure (placebo, negative control)
2. Level of Stromelysin-1 in serum of the human volunteers treated with the antioxidant of the present invention (50 to 500 mg/day for one to 4 weeks) after sun exposure

25

At the conclusion of the study, the pre- and post-study stromelysin-1 level would be compared to determine if any significant changes are observed.

30

## EXAMPLE 11

CONTEMPLATED LANGERHANS CELLS (LC) AS A BIOMARKER FOR  
EVALUATION OF THE EXTRACT COMPOSITION OF INVENTION TO  
5 ALTER UV-INDUCED SKIN DAMAGE BY ORAL ADMINISTRATION

Exposure to sunlight or UV irradiation produces marked and significant changes in LC in the human skin. The LC count is reduced as a function of UV dose. They lose their dendritic morphology and ball up. The LC lose  
10 their antigen-presenting ability. These two variables can be detected and followed with the aid of ATPase staining technology ( K Wolff and G. Stibgl, J. Invest. Dermatol, 80, 17s-21s, 1983).

1. Level of LC in skin of the human volunteers before sun exposure  
15 (placebo, negative control)
2. Level of LC in skin of the human volunteers orally administered with the antioxidant of the present invention (50 to 500 mg/day for one to 4 weeks) after sun exposure

At the conclusion of the study, the pre- and post-study LC level would be  
20 compared to determine if any significant changes are observed.

## EXAMPLE-12

CONTEMPLATED LIPID PEROXIDES AS A BIOMARKER FOR  
25 EVALUATION OF THE EXTRACT COMPOSITION OF INVENTION TO  
ALTER UV-INDUCED SKIN DAMAGE BY ORAL ADMINISTRATION

Exposure to sunlight or UV irradiation produces oxidative stress and significant changes in lipid peroxide level in the human skin. The level of  
30 lipid peroxide level can be detected and followed by the procedure described by P. Pugliese, Assessment of anti-aging products, In Clinical

Safety and efficacy testing of Cosmetics, Vol 1, Marcel Dekker, NY, 295-309, 1990.

1. Level of lipid peroxides in skin of the human volunteers before sun exposure (placebo, negative control)
  - 5 2. Level of lipid peroxides in skin of the human volunteers orally administered with the antioxidant of the present invention (50 to 500 mg/day for one month to two months, once or twice daily) after sun exposure
- 10 At the conclusion of the study, the pre- and post-study lipid peroxide level would be compared to determine if any significant changes are observed.

15 It is believed that results of the protocol described above would establish scientifically the effectiveness of oral administration of the extract composition of the invention on control or protection of skin upon exposure to UV radiation.

20 The efficacy of protection is not comparable, however, with the use of sunscreen with a broad and high sun protection factor, but dietary supplement of the present invention may be used to increase the basal protection and thus increase the defense against UV-light mediated damage to skin. The present invention may be complemented with regular use of sunscreens applied topically, especially a sunscreen containing an extract of *Emblica officinalis*, especially the standardized extract.

25 Accordingly, one aspect of the invention is to provide a regimen wherein a person will administer a topical sunscreen to the person's skin and before and/or during exposure to sun, the person will ingest a composition containing an extract of *Emblica officinalis*, preferably a standardized extract. Preferred regimens comprises orally administering the extract-

30 containing composition before sun exposure, for example at least one week, or at least 2 or 3 days before sun exposure. The contemplated



dosage is a sufficient to ameliorate damage to skin from exposure to sun, e.g. 1-500, preferably 2-200 mg of the standardized extract per day.

5 The preceding examples can be repeated with similar success by blending one or more hydrophobic antioxidants, such as, Vitamin E, Lipoic Acid, Carotenoids, lutein, melatonin, with the antioxidant of the present invention generically or specifically described operating conditions of this invention for those used in the preceding examples.

10 The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

The entire disclosure of all applications, patents and publications, cited above and below, including but not limited to U.S. Patent 6,124,268 issued September 26, 2000, copending Application serial no. 10/120,156  
15 filed April 11, 2002, and Provisional application 60/395,612 filed July 15, 2002 are hereby incorporated by reference.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and  
20 modifications of the invention to adapt it to various usages and conditions.

25

30

## WHAT IS CLAIMED IS:

- 5 1. Non-therapeutic use of an extract of *Emblica officinalis* to retard, prevent and / or reverse the sign of skin photo-damage.
- 10 2. Use of an extract of *Emblica officinalis* for the production of a medicament suitable for the prophylaxis and / or treatment of the signs of skin photo-damage.
3. Dosage form suitable for oral administration, characterized in that it comprises an extract of *Emblica officinalis*.
- 15 4. Dosage form according to claim 3, which includes excipients suitable for such oral administration.
- 20 5. Dosage form according to claim 3, wherein the dosage form is a tablet or a capsule or an elixir or suspension or a drink.
- 25 6. Dosage form according to at least one of the preceding claims, wherein said dosage form contains other ingredient capable of retarding, preventing and reversing the sign of skin photo-damage.
- 30 7. Dosage form according to at least one of the preceding claims, wherein said extract includes Emblicanin A, Emblicanin B, Pendunculagin and Punigluconin, preferably in an amount of >40% by weight of the extract.
8. Dosage form according to at least one of the preceding claims, wherein total flavonoids are present in the extract in

an amount < 1% by weight of the extract and preferably rutin species of flavonoids are present in an amount of only 0.0001 to 0.01%.

- 5            9.       Dosage form according to at least one of the preceding claims, wherein said extract is a standardized extract.
- 10           10.      Dosage form according to at least one of the preceding claims, wherein the dosage form is a nutritional supplement, preferably in the form of liquids, powders, pills or tablets and confectionery bars, especially preferred a baked, edible, high protein product.
- 15           11.      Dosage form according to claim 10, comprising a) at least 0.1% *Emblica officinalis* extract, b) a mixture of high protein components, c) flour, d) leavening agent, e) sweetener, and f) water.
- 20           12.      Dosage form according to at least one of claims 10 or 11, comprising a flavor component for imparting a characteristic taste to said nutritional composition selected from the group consisting of water soluble natural or artificial extracts that include apple, banana, cherry, cinnamon, cranberry, grape, honeydew, honey, kiwi, 25 lemon, lime, orange, peach, peppermint, pineapple, raspberry, tangerine, watermelon, wild cherry and equivalents thereof; being in the overall range of 0.10% to 2.0% by weight of said dry composition.
- 30           13.      Dosage form according to at least one of claims 10 to 12, comprising a colorant component for imparting a characteristic color to said nutritional composition selected

5 from the group consisting of water soluble natural or artificial dyes of blue, green, orange, red, violet, and yellow; iron oxide dyes, ultramarine pigments of blue, pink, red, and violet; and equivalents thereof; being in the overall range of 0.10% to 2.0% by weight of said dry composition.

10 14. Use according to at least one of claims 1 or 2, wherein the effective dose of the extract is in the range of about 1 to 500 mg of said extract per day, preferably in the range of about 2 to 200 mg of said extract per day.

15 15. Use according to at least one of claims 1, 2 or 9, wherein administration of said effective dose is begun before, during or after sun exposure, preferably two to three days before sun exposure, especially preferred a week before sun exposure.

20 16. Use according to at least one of claims 1, 2, 9 or 10, wherein additionally a sunscreen is administered topically to the skin of a human subject during sun exposure.

25 17. Use of an extract of *Emblica officinalis* for the reduction or inhibition of UV-induced Metallo Matrix Protein activity (MMP-activity), preferably for the reduction or inhibition of UV-induced Collagenase activity.

30 18. Use of an extract of *Emblica officinalis* for the reduction or inhibition of UV-induced Stromelysin-1 activity.

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/EP 03/11847

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K7/42 A61K35/78

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 00 48551 A (NATREON INC) 24 August 2000 (2000-08-24) page 3, line 15-17; claims 1,10,11,19,20,23,24 page 6 examples 8-16 page 9, line 18 - line 26 page 21 -page 26	1-7, 10-16 8,9
X	US 6 362 167 B1 (GHOSAL SHIBNATH) 26 March 2002 (2002-03-26) column 1, line 17 - line 23; claims 7,8 column 1, line 54,55 column 2, line 30-33 column 4, line 6 - line 42 column 7, line 22 - line 35	1-7,10
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 January 2004

Date of mailing of the international search report

04/02/2004

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo.nl,  
Fax: (+31-70) 340-3016

Authorized officer

Loloiu, C

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/11847

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1, 17-18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/11847

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHAUDHURI R K: "EMBLICA CASCADING ANTIOXIDANT: A NOVEL NATURAL SKIN CARE INGREDIENT" SKIN PHARMACOLOGY AND SKIN APPLIED PHYSIOLOGY, KARGER, BASEL,, CH, vol. 15, no. 5, 2002, pages 374-380, XP008016256 ISSN: 1422-2868	1,2
Y	abstract page 375, column 1 page 379	8,9
X	CHAUDHURI R K: "BEARING FRUIT A NEW STUDY HAS PROVED THE SKIN CARE BENEFITS OF A PRODUCT DERIVED FROM A TRADITIONAL AYURVEDIC INGREDIENT" SOAP PERFUMERY AND COSMETICS, UNITED TRADE PRESS LTD. LONDON, GB, vol. 74, no. 8, August 2001 (2001-08), pages 28-30, XP008016231 ISSN: 0037-749X page 28, column 2 page 29	1,2, 14-16
Y		8,9
A	BHATTACHARYA A ET AL: "ANTIOXIDANT ACTIVITY OF ACTIVE TANNOID PRINCIPLES OF EMBLICA OFFICINALIS (AMLA)" INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, XX, XX, vol. 37, no. 7, July 1999 (1999-07), pages 676-680, XP008016252 ISSN: 0019-5189 the whole document	1,2

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/11847

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0048551	A	24-08-2000	US 6124268 A	26-09-2000
			US 6235721 B1	22-05-2001
			AU 2999400 A	04-09-2000
			CA 2362346 A1	24-08-2000
			EP 1156770 A1	28-11-2001
			WO 0048551 A1	24-08-2000
			US 6290996 B1	18-09-2001
			US 6362167 B1	26-03-2002
US 6362167	B1	26-03-2002	US 6124268 A	26-09-2000
			US 6235721 B1	22-05-2001
			AU 9280601 A	02-04-2002
			CA 2407465 A1	28-03-2002
			EP 1318721 A1	18-06-2003
			WO 0223995 A1	28-03-2002
			AU 2999400 A	04-09-2000
			CA 2362346 A1	24-08-2000
			EP 1156770 A1	28-11-2001
			WO 0048551 A1	24-08-2000
			US 6290996 B1	18-09-2001